Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Other Non-Current Liabilities of $500000.0 for Q1 2026, down 10.39% year-over-year from $558000.0 in Q1 2025, and little changed quarter-over-quarter from $500000.0 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $500000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 10.39% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $500000.0 (down 10.39% YoY), while the FY2025 annual figure was $500000.0, down 41.11% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $500000.0, roughly flat from $500000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $45.0 million in Q1 2022, with the low at $500000.0 in Q2 2023.
- The 5-year median for Other Non-Current Liabilities is $996000.0 (2024), against an average of $4.0 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 10168.95% in 2022, then plunged 96.02% in 2023.
- Zentalis Pharmaceuticals' Other Non-Current Liabilities stood at $2.6 million in 2022, then plunged by 32.06% to $1.8 million in 2023, then sank by 52.3% to $849000.0 in 2024, then plunged by 41.11% to $500000.0 in 2025, then changed by 0.0% to $500000.0 in 2026.
- Business Quant data shows ZNTL's Other Non-Current Liabilities at $500000.0 in Q1 2026, $500000.0 in Q4 2025, and $500000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Dec 31, 2024 | 849,000.00 |
| Sep 30, 2024 | 996,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Mar 31, 2022 | 44.98 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Jun 30, 2021 | 296,000.00 |
| Mar 31, 2021 | 438,000.00 |
| Dec 31, 2020 | 1.10 Mn |